微小染色体维持蛋白-2和CD24在非小细胞肺癌中的表达及其与预后的关系

Expression of the minichromosome maintenance 2 protein and the cell surface molecule CD24 and their prognostic significance in patients with non-small cell lung cancer

目的探讨微小染色体维持蛋白-2（MCM2）和CD24在非小细胞肺癌中的表达及其与预后的关系。方法选取在我院初诊并手术的73例非小细胞肺癌（non—small cell lung cancer，NSCLC）患者，应用免疫组织化学方法检测其病理组织标本中MCM2和CD24的表达，回顾性分析其表达与患者预后的关系。结果73例NSCLC中分别有42例和54例呈MCM2和CD24高表达，各占57．5％和74．0％。MCM2和CD24高表达患者的死亡风险较低表达者均显著升高（P〈0．05）。MCM2和CD24均高表达患者的死亡风险显著高于其中仅一项高表达者（HR=2．59，95％CI1．40～4．80，P=0．002）和两项均低表达者（HR=15．32，95％CI=2．07～113．41，P=0．008），而一项高表达者与两项均低表达者相比死亡风险升高无统计学意义（HR=5．60，95％CI=0．79～44．82，P=0．083），两项均高表达者的累积生存率显著低于一项高表达者（P=0．001）和两项均低表达者（P=0．001）。结论MCM2和CD24均是NSCLC的独立预后因素，两者联合检测对NSCLC患者预后的评估价值更高。

Objective To explore expression of the minichromosome maintenance 2 （MCM2） protein and the mucin-like cell surface adhesion molecule CD24 in non-small cell lung cancer （NSCLC） and their relationship with its prognosis. Methods Seventy-three patients of NSCLC diagnosed for the first time and received surgical treatment in Xuanwu Hospital, Beijing were selected for the study. Expression of the MCM2 and CD24 in pathological specimens of the patients was measured by immunohistochemistry and their relationship with its prognosis was analyzed retrospectively. Results High-level expression of the MCM2 and CD24 was seen in 42 and 54 of 73 NSCLC patients, accounting for 57. 5 percent and 74. 0 percent, respectively. Risk of death for the patients with high-level expression of the MCM2 or the CD4 was significantly higher as compared to those with low-level expression （ P 〈 0. 05 ）. Risk of death for patients with both high-level expression of the MCM2 and CD24 was significantly higher than that in those with only high-level expression of the MCM2 or the CD24 （HR =2. 59, 95% CI 1.40 -4. 80, P =0. 002） and in those with both low-level expression of them （HR = 15.32, 95% CI = 2. 07 - 113.41, P = 0. 008）. But there was no significant difference in risk of death between patients with high-level expression of the MCM2 or CD24 and those with low-level expression of both of them （HR = 5.60, 95% CI O. 79 -44. 82, P =0. 083 ） , and cumulative survival rate of patients with both high-level expression of the MCM2 and CD24 was significantly lower than those with only high-level expression of the MCM2 or the CD24 （ P = 0. 001 ）. Conclusions Both expression of the MCM2 and the CD24 are independent prognostic factors for NSCLC and combined detection of the two markers have higher prognostic value for it.